radium225

Radium-225 is a radioactive isotope of radium with a half-life of 14.9 days. It is a beta emitter and decays into actinium-225. Radium-225 is one of the decay products of uranium-233 and thorium-229, and it is found in trace amounts in uranium ores.

Radium-225 has been investigated for use in targeted alpha therapy (TAT), a type of cancer treatment. In TAT, a radioactive isotope is attached to a molecule that targets cancer cells. When the radioactive isotope decays, it emits alpha particles, which can damage and kill cancer cells. Radium-225's relatively short half-life and its ability to emit alpha particles make it a promising candidate for TAT.

The decay chain of radium-225 is complex and includes several other radioactive isotopes, such as actinium-225, bismuth-213, and polonium-213. These daughter isotopes are also alpha emitters, and their properties are important considerations for the use of radium-225 in medical applications. Due to its radioactivity, radium-225 must be handled with care and appropriate safety precautions.